Flash Finance

Biocon LimitedBIOCONCorporate

Healthcare Biotechnology Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹349.20
MCap ₹56,860 Cr · P/E 136.4
Biocon Limited — Stock analysis & AI research Biocon Limited — Multibagger AI analysis Biocon Limited — Seasonality — best & worst months Biocon Limited — Technical indicators & charts Biocon Limited — Technical setup — score, trend, support & resistance Biocon Limited — Double Top pattern broken down ↓ Biocon Limited — Live exchange announcements
📋 Mid Cap Stocks List 📈 Death Cross Stocks📈 RSI Oversold Stocks📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹4,336 Cr
Sales · Jun 2026
+10.0% YoY
₹847 Cr
Operating Profit · Jun 2026
+13.1% YoY
19.5%
OPM % · Jun 2026
+2.6% YoY
₹137 Cr
Net Profit · Jun 2026
+53.4% YoY
₹0.87
EPS · Jun 2026
+234.6% YoY

📝 Biocon Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Biocon Limited reported revenue of ₹4,336 crore for the quarter ended June 2026 (Q1 FY27), up 10.0% from ₹3,942 crore in the same quarter last year, and down 4.0% sequentially over the March 2026 quarter.

Net profit rose 53.4% year-on-year to ₹137 crore, from ₹89 crore. Earnings per share (EPS) came in at ₹0.87.

Operating profit stood at ₹847 crore — an operating margin (OPM) of 19.5%, compared with 19.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Biocon Limited posted revenue of ₹16,927 crore, a growth of 10.9% over FY25, with a net profit of ₹369 crore (down 74.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹17,322 crore with a net profit of ₹417 crore.

Valuation snapshot

At the current price of ₹349.20, BIOCON has a market capitalisation of ₹56,860 crore and a trailing P/E of about 136.4.

Within the Biotechnology industry, it is the largest of the 8 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 44.68%, foreign institutional investors (FIIs) 8.16%, domestic institutional investors (DIIs) 23.37%, public shareholders 23.74% of Biocon Limited.

Promoter holding slipped from 44.91% to 44.68% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹56,860 Cr
Current Price ?
₹349.2
P/E ?
136.42above ind
Industry P/E ?
106.70
P/B ?
1.67
P/S ?
3.28
P/FCF ?
693.41
Enterprise Value ?
₹72,294 Cr
EV/EBITDA ?
20.44
PEG ?
N/A
Earnings Yield ?
2.1%
Dividend Yield ?
0.14%
Profitability & Returns
Sales (TTM) ?
₹17,322 Cr
OPM ?
20.4%
Profit after tax (TTM) ?
₹417 Cr
EPS (TTM) ?
₹2.56
ROCE ?
4.0%
ROE ?
1.2%
ROA ?
0.7%
Growth
Sales — latest qtr ?
₹4,336 Cr
PAT — latest qtr ?
₹137 Cr
YoY qtr sales growth ?
10.0%
YoY qtr profit growth ?
53.4%
Sales growth (3y) ?
15%
Sales growth (5y) ?
19%
Profit growth (3y) ?
-15%
Profit growth (5y) ?
-12%
Financial Health
Debt ?
₹15,434 Cr
Debt to Equity ?
0.45
Interest Coverage ?
1.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
44.68%
Change in promoter holding ?
-9.77%
Pledged percentage ?
N/A
Market
Return 3 months ?
-20.1%
Return 6 months ?
-2.5%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 2,9413,7743,4233,4623,9543,9173,4333,5903,8214,4173,9424,2964,1734,5174,336 +10.0% -4.0%
Operating Profit 6449976817179279136206857521,0787498358341,020847 +13.1% -16.9%
Other Income 7915594134566401,1343235378093117-2854 -31.6% +294.6%
Interest 120249233248267227236226223212277272210232213 -22.9% -8.1%
Depreciation 301364358389414407405420425436455473515513547 +20.3% +6.7%
Profit Before Tax -264971842148083191,1469815648797171-68248128 +31.7% -48.5%
Net Profit -21414149173753223862278145989133-52199137 +53.4% -31.3%
EPS -0.352.620.841.055.521.135.51-0.130.212.880.260.661.080.780.87 +234.6% +11.5%
OPM % 21.9% 26.4% 19.9% 20.7% 23.4% 23.3% 18.1% 19.1% 19.7% 24.4% 19.0% 19.4% 20.0% 22.6% 19.5% +2.6% -13.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹15,262 Cr ₹16,927 Cr ₹17,322 Cr +10.9%
Operating Profit ₹3,136 Cr ₹3,438 Cr ₹3,536 Cr +9.6%
OPM % 20.55% 20.31% 20.41% -1.2%
NPM % 9.37% 2.18% 2.41% -76.7%
Other Income ₹1,239 Cr ₹262 Cr ₹237 Cr -78.8%
Depreciation ₹1,687 Cr ₹1,956 Cr ₹2,049 Cr +16.0%
Interest ₹897 Cr ₹991 Cr ₹927 Cr +10.4%
EBIT ₹1,449 Cr ₹1,482 Cr ₹1,487 Cr +2.3%
PBT ₹1,887 Cr ₹448 Cr ₹479 Cr -76.2%
Tax ₹457 Cr ₹30 Cr ₹13 Cr -93.4%
Net Profit ₹1,429 Cr ₹369 Cr ₹417 Cr -74.2%
EPS ₹8.47 ₹2.78 ₹3.39 -67.2%
Material Cost ₹4,903 Cr ₹5,059 Cr ₹4,804 Cr +3.2%
Employee Cost ₹3,144 Cr ₹2,596 Cr ₹2,679 Cr -17.4%
Extraordinary Items ₹96 Cr ₹-305 Cr ₹-319 Cr -416.4%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 600600600810 +35.0%
Reserves 17,26719,18321,04433,221 +57.9%
Borrowings 18,01916,27718,36215,434 -15.9%
Other Liabilities 15,85619,69318,53414,185 -23.5%
Total Liabilities 51,74255,75358,54063,651 +8.7%
Fixed Assets 29,46830,64431,96338,860 +21.6%
CWIP 7,3177,9938,5084,613 -45.8%
Investments 2,0691,0001,1271,779 +57.9%
Other Assets 12,88816,11716,94118,399 +8.6%
Total Assets 51,74255,75358,54063,651 +8.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,8522,9544,0611,994 -50.9%
Cash from Investing Activity -14,260-1,002-203-2,082 -925.6%
Cash from Financing Activity 13,049-2,333-1,854-924 +50.2%
Net Cash Flow 641-3802,004-1,012 -150.5%
Free Cash Flow 1291,0461,71882 -95.2%
CFO/OP 86%101%139%65% -53.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 117154131129 -1.5%
Inventory Days 423368346390 +12.7%
Days Payable 383467460434 -5.7%
Cash Conversion Cycle 157551885 +372.2%
Working Capital Days 3-68-63-2 +96.8%
ROCE % 6%6%6%4% -33.3%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 54.45%54.45%54.45%44.91%44.68% -0.5%
FIIs 6.04%6.61%7.39%7.52%8.16% +8.5%
DIIs 22.83%22.06%21.67%24.01%23.37% -2.7%
Government 0.00%0.03%0.03%0.05%— —
Public 16.51%16.70%16.34%23.40%23.74% +1.5%
Others 0.18%0.14%0.12%0.09%— —
No. of Shareholders 4,28,1314,13,1913,94,2793,86,5933,92,509 +1.5%

⚖️ Peer comparison

Industry: Biotechnology · 8 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 BIOCON Biocon ₹390.65 63,609 147.4 17,322 417 20.4% 2.4% 10.9% -74.2% 10.0% 53.4%
2 ANTHEM ANTHEM BIOSCIENCES ₹874.85 49,142 85.4 2,002 576 39.6% 28.8% — — -22.6% -11.7%
3 ONESOURCE ONESOURCE SPECL ₹1,592.00 18,256 — 1,544 -49 21.9% -3.2% -1.6% -185.0% 37.3% 0.7%
4 CONCORDBIO Concord Biotech ₹1,510.00 15,797 57.6 1,109 273 34.9% 24.6% -12.1% -30.4% 26.2% 31.0%
5 514336 CCME Global ₹15.10 150 — 0 -1 -2079.0% -2135.5% -98.9% -120.3% — -120.2%
6 511509 Vivo Bio ₹37.69 37 — 55 -3 37.0% -5.2% 14.3% -123.4% 14.1% -86.0%
7 539470 Shree Ganesh ₹1.20 18 — 5 -0 -35.3% -7.8% -78.4% 34.2% 3.6% -273.7%
8 539206 Genomic Valley ₹52.00 9 n/m 0 0 11.7% 6.7% -68.2% -94.4% -57.8% -26.9%
❓ Frequently asked questions
What was Biocon Limited's revenue in Q1 FY27?
Biocon Limited reported revenue of ₹4,336 crore for the quarter ended June 2026 (Q1 FY27), up 10.0% from ₹3,942 crore in the same quarter last year, and down 4.0% sequentially over the March 2026 quarter.
What was Biocon Limited's net profit in Q1 FY27?
Net profit rose 53.4% year-on-year to ₹137 crore, from ₹89 crore. Earnings per share (EPS) came in at ₹0.87.
What is BIOCON's market capitalisation and P/E ratio?
At the current price of ₹349.20, BIOCON has a market capitalisation of ₹56,860 crore and a trailing P/E of about 136.4.
Who owns Biocon Limited? (shareholding pattern)
As of Jun 2026, promoters held 44.68%, foreign institutional investors (FIIs) 8.16%, domestic institutional investors (DIIs) 23.37%, public shareholders 23.74% of Biocon Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI